ReviewCureus2025
Impact of Blood Pressure Control on Stroke and Myocardial Infarction Risk in Hypertensive Patients With and Without Diabetes: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.JAMA cardiology · 2026Trial
- Redefining Therapeutic Targets in Hypertension and Cardiometabolic Syndrome.Circulation research · 2026Review
- Digital pharmacoepidemiology of angiotensin-converting enzyme inhibitors in Russia.Frontiers in pharmacology · 2026Article
- Comparative Effectiveness of SGLT2i and GLP-1RA on Blood Pressure in Hypertensive Patients with Type 2 Diabetes: A Saudi Multicenter Retrospective Study.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension (HTN) is a well-acknowledged and modifiable risk factor that significantly increases the risk of cardiovascular disease. Left uncontrolled, HTN may result in severe complications, including myocardial infarction and stroke. Also, when HTN coexists with diabetes, the adverse effects on cardiovascular health are amplified as a result of the combined vascular and metabolic effects. This narrative review synthesizes evidence from large observational cohorts, randomized clinical trials (e.g., Systolic Blood Pressure Intervention Trial or SPRINT, Action to Control Cardiovascular Risk in Diabetes or ACCORD), and contemporary guideline recommendations to assess these outcomes. The coexistence of diabetes mellitus with hypertension may further worsen vascular health through combined metabolic and endothelial effects, increasing rates of myocardial infarction and stroke. While pharmacological blood pressure (BP) lowering and lifestyle interventions (e.g., sodium restriction, exercise) generally reduce risk, overly aggressive diastolic BP reduction (< 60 mmHg) can pose hazards in older adults or patients with chronic kidney disease. Current strategies adjust systolic and diastolic targets based on individual factors, age, comorbidity burden, and baseline cardiovascular risk and may include combined drug regimens, dietary counseling, or device‑based therapies. Further studies should prospectively evaluate optimal BP targets in under‑represented populations (e.g., elderly ≥ 75 years, chronic kidney disease stages 3-5, sub‑Saharan cohorts) and compare pharmacologic versus lifestyle‑only strategies, particularly in patients with multiple comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.